Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pexidartinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R known ✓ | P07333 | 4/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 0.98 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.98 |
| ▸ | FLT1 | P17948 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pexidartinib SCHEMBL29772694 | 1.00 | CSF1R (0.98) | CSF1RKITLCKPGRCHRM2 | |
| Pexidartinib SCHEMBL18207396 | 1.00 | CSF1R (0.98) | CSF1RKITLCKPGRCHRM2 | |
| Pexidartinib SCHEMBL29380288 | 0.99 | CSF1R (1.00) | CSF1RKITLCKPGRCHRM2 | |
| Pexidartinib SCHEMBL29361827 | 0.99 | CSF1R (1.00) | CSF1RKITLCKPGRCHRM2 | |
| Pexidartinib SCHEMBL1267310 | 0.99 | CSF1R (1.00) | CSF1RKITLCKPGRCHRM2 | |
| Pexidartinib SCHEMBL28365567 | 0.97 | CSF1R (0.93) | CSF1RKITLCKPGRCHRM2 | |
| SCHEMBL20682173 | 0.91 | CSF1R (0.85) | CSF1RKITLCKPGRCHRM2 | |
| SCHEMBL22839405 | 0.91 | CSF1R (0.85) | CSF1RKITLCKPGRCHRM2 | |
| SCHEMBL15984524 | 0.91 | CSF1R (0.85) | CSF1RKITLCKPGRCHRM2 | |
| SCHEMBL1266891 | 0.89 | CSF1R (0.81) | CSF1RKITLCKPGRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2023230233-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2023220192-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | FOUNDATION MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2022-08-11 | — | — | US | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20260148807-A1 | DETERMINING A CONDITION USING FRAGMENTOMIC ENDPOINT DATA | FOUNDATION MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260148859-A1 | METHODS AND SYSTEMS FOR PREDICTING A CUTANEOUS PRIMARY DISEASE SITE | FOUNDATION MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260148805-A1 | DETERMINING A PREDICTIVE PROFILE BASED ON FRAGMENTOMIC FEATURES | FOUNDATION MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260146290-A1 | DETERMINING A TARGET CONDITION BASED ON FRAGMENTOMIC FEATURES OF NON-TARGET CELLS | FOUNDATION MEDICINE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | disclosed |
| US-20220036993-A1 | PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY (REMS) | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20220034871-A1 | METHODS FOR ADMINISTERING PEXIDARTINIB | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-03 | — | — | US | disclosed |
| WO-2022018667-A1 | COMBINATION THERAPIES USING CDK2 AND CDC25A INHIBITORS | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022018596-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260148807-A1 | DETERMINING A CONDITION USING FRAGMENTOMIC ENDPOINT DATA | DNMT3A, EWSR1, FGFR2 | CSF1R 1523/4885KIT 4187/4885FLT3 421/4885 |
| US-20260146290-A1 | DETERMINING A TARGET CONDITION BASED ON FRAGMENTOMIC FEATURES OF NON-TARGET CELLS | MRE11, PCNA, EWSR1 | CSF1R 3430/4885KIT 3203/4885FLT3 991/4885 |
| US-20220034871-A1 | METHODS FOR ADMINISTERING PEXIDARTINIB | PEX3, GLS2, GLS | CSF1R 130/4885KIT 2265/4885FLT3 54/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | CSF1R 1496/4885KIT 3807/4885FLT3 2546/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | CSF1R 135/4885KIT 104/4885FLT3 5/4885 |
| US-20260148805-A1 | DETERMINING A PREDICTIVE PROFILE BASED ON FRAGMENTOMIC FEATURES | BRCA1, UBE2V1, TSG101 | CSF1R 3045/4885KIT 4154/4885FLT3 3833/4885 |
| US-20260148859-A1 | METHODS AND SYSTEMS FOR PREDICTING A CUTANEOUS PRIMARY DISEASE SITE | BRCA1, UNG, LIG3 | CSF1R 1506/4885KIT 789/4885FLT3 615/4885 |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, TEKT1, NTSR1 | CSF1R 269/4885KIT 2626/4885FLT3 372/4885 |
| US-20220036993-A1 | PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY (REMS) | PEX3, GLS2, PLPBP | CSF1R 56/4885KIT 4135/4885FLT3 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.